List of Clinical Trials

Updated May 27, 2016

In addition to the therapies approved by Health Canada, patients may be able to access several other therapies through clinical trials. By participating in a clinical trial, you will be helping researchers answer important questions that will further the development of new treatments and new treatment guidelines. Also, clinical trials often give you another option in your treatment plan.

Kidney Cancer Canada makes every effort to be aware of major clinical trials for renal cell carcinoma across Canada. As a patient with renal cell carcinoma, you may be eligible to access a therapy through a clinical trial depending upon:

  • Your sub-type of kidney cancer (e.g., clear cell renal cell carcinoma or other)
  • Your stage of disease (e.g., whether or not you have metastasis)
  • Whether you have had one or more prior therapies

For ease of reference, we have organized major clinical trials into groupings below according to where you are on the treatment journey. For example, you’ll find trials for patients who have just recently been diagnosed and are pre-surgery or clinical trials for those for patients who have already had several systemic therapies.

 

Pre-Surgery (NeoAdjuvant) Trials

The purpose of NeoAdjuvant trials is to determine whether treatments that are proven to be effective with metastatic kidney cancer can also be used effectively before surgery to reduce the size of tumours.

 

Trial ID: NCT02212730
A Study Evaluating the Effect of Neoadjuvant Pembrolizumab (MK-3475) in Renal Cell Cancer Patients Undergoing Surgical Resection (MK-3475-031)
Princess Margaret Centre Toronto Recruiting
Merck Canada Kirkland, QC Recruiting

Trial ID: NCT01099423
Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME)
Princess Margaret Centre Toronto Recruiting
Ottawa Hospital Ottawa Recruiting
CHUM - Pavillon Saint-Luc Montreal Recruiting
Queen Elizabeth II Health Sciences Centre Halifax Recruiting

Primary Treatment Trials

 

Trial ID: NCT01529658 
Renal Hypothermia During Partial Nephrectomy
St. Joseph's Health Centre Hamilton Recruiting 
London Health Sciences Centre London Recruiting
The Ottawa Hospital Ottawa Recruiting 
Princess Margaret Cancer Centre/UHN Toronto Recruiting
Centre hospitalier universitaire de Québec Quebec Recruiting
QE II Health Sciences Centre Halifax Recruiting

Trial ID: NCT01720706 
Thermal Ablation in Larger Liver and Kidney Tumours
University of Health Network (UHN) Toronto Recruiting 

Trial ID: NCT01305330
The Natural History of Small Renal Masses (Role of Active Surveillance and Identification of Prognostic Factors for Progression in Early Stage RCC)
Princess Margaret Hospital/University Health Network Toronto Recruiting

 Trial ID: AGS-003-007 (Argos Therapeutics, Inc.)
Trial of Autologous Dendritic Cell Immunotherapy (AG3-003), plus Standard Treatment in People with Advanced Renal Cell Carcinoma Who Have Not Undergone a Nephrectomy
St. Joseph’s Healthcare, Institute of Urology Hamilton Recruiting

Post-Surgery with no Metastases (Adjuvant) Trials

The purpose of Adjuvant trials is to determine whether treatments that are proven to be effective with metastatic kidney cancer can also be used effectively to slow or prevent recurrence after surgical treatment.

 

No adjuvant trials are available in Canada at this time 

First Line Treatment (means no prior systemic therapy)

In addition to proven first-line treatments for kidney cancer, patients who have not had any prior systemic therapy for their metastatic disease have several treatment options.

 

Trial ID: NCT02019576
Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib 
BC Cancer Agency-Vancouver Vancouver Not yet recruiting
Tom Baker Cancer Centre Calgary Not yet recruiting
Cross Cancer Institute Edmonton Not yet recruiting
CancerCare Manitoba Winnipeg Not yet recruiting
Juravinski Cancer Centre Hamilton  Not yet recruiting
London Health Sciences Centre London Not yet recruiting
Ottawa Hospital Cancer Centre Ottawa Not yet recruiting
Sunnybrook Health Sciences Centre Toronto Recruiting
Princess Margaret Cancer Centre Toronto Not yet recruiting
Jewish General Hospital Montreal Not yet recruiting
CHUM, Hôpital Notre-Dame Montreal Recruiting
McGill University Health Centre Montreal Not yet recruiting
QEII Health Sciences Centre Halifax Not yet recruiting

Trial ID: NCT02420821 
A Study of Atezolizumab (an Anti-Programmed Death Ligand 1 (PD-
L1) Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma [IMmotion151]
London Regional Cancer Centre London Recruiting
Sunnybrook Health Sciences Centre Toronto Not yet recruiting
Princess Margaret Cancer Centre Toronto Not yet recruiting
Juravinski Cancer Centre Hamilton Recruiting
Ottawa Hospital Cancer Centre  Ottawa Active, not recruiting 
Durham Regional Cancer Centre Oshawa Recruiting
Royal Victoria Regional Health Centre Barrie Active, not recruiting
Jewish General Hospital Montreal Recruiting
Hôtel Dieu de Québec Quebec Recruiting
QEII Health Sciences Centre Halifax Recruiting

Trial ID: NCT02231749
Nivolumab Combined with Ipilimumab versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) 
Cross Cancer Institute Edmonton Recruiting
Tom Baker Cancer Centre Calgary Recruiting
BC Cancer Agency Vancouver Recruiting
Princess Margaret Cancer Centre Toronto Recruiting
Sunnybrook Odette Cancer Centre Toronto Recruiting
Centre D'Oncologie Dr-Leon-Richard Moncton Recruiting
McGill University, Department of Oncology Montreal Recruiting

Second Line Treatment (only one prior systemic therapy)

 

Trial ID: NCT02761057
A Study of Cabozantinib(Cometriq®, BMS-907351), or Crizotinib (Xalkori®), or Volitinib (AZD6094, Savolitinib), or Sunitinib (Sutent®) in Treating Patients With Locally Advanced (spread from where it started in the kidney to nearby tissue or lymph nodes) or Metastatic Papillary Kidney Cancer (also called the PAPMET study). Patients may have had prior surgery, 1 prior systemic therapy or prior radiation therapy for advanced or metastatic kidney cancer.
We do not have a list of participating Canadian centres to date (August 18, 2016).   Recruiting

 

Trial ID: NCT01482949
A Rollover Study Testing the Biologic Activity and Safety of AGS-003 in Renal Cell Carcinoma Subjects with Prolonged Response or Stable Disease and Ongoing AGS-003 Treatment in Protocol AGS-003-004 or AGS-003-006
Jewish General Hospital  Montreal Recruiting

Trial ID: NCT02298959
Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumours, including Metastatic or Recurrent Renal Cell Cancer after receiving at least one prior vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI )
BC Cancer Agency Vancouver Recruiting
Princess Margaret Hospital  Toronto Recruiting

Trial ID: NCT02304393
An Open-label, 3-part Study of RO7009789 (a CD40 Agonist) in Combination with a drug called atezolizumab or MPDL3280A (an Anti-PD-L1) in Patients with Locally Advanced and/or Metastatic Solid Tumours.  Note: Tumours must be able to be biopsied.  Patients cannot have had prior immuno-oncology drug treatment with anti-CTLA4, anti-PD-1, or anti-PD-L1 drugs, or drugs that target CD40.
Jewish General Hospital Montreal Recruiting
Princess Margaret Hospital Toronto Pending

Trial ID: NCT02665416
An Open-label, 2-part Study to assess the safety and effectiveness of an experimental drug called RO7009789 (a CD40 Agonist) in Combination with Vanucizumab (a VEGF Inhibitor) in Patients with Advanced or Metastatic Solid Tumours (including kidney cancer).  Note: Patients cannot have had prior treatment with a VEGF inhibitor within 12 months of going on this study.
Princess Margaret Hospital Toronto Recruiting

Third Line Treatment (up to two prior systemic therapies)



Trial ID: NCT02460224
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (including Renal Cancer)
Novartis Investigative Site Toronto Recruiting

Trial ID: NCT02754141
A Study to assess the Safety and Effectiveness of an experimental drug called BMS-986179 when given along with Nivolumab (Opdivo®) (an immuno-oncology drug) in Patients with Advanced Solid Tumours (including kidney cancer).
Princess Margaret Hospital Toronto Pending
Ottawa Hospital Ottawa Pending

Other Clinical Trials (not included under categories above)



Trial ID: NCT00323076
Imaging Study (PET Imaging) in Patients With Cancer of the Head and Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
Cross Cancer Institute Edmonton Recruiting

Trial ID: NCT01446744
Stereotactic Ablative Radiation Therapy for Comprehensive Treatment of Oligometastatic Tumours (SABR-COMET)  
BC Cancer Agency Vancouver Recruiting
London Health Sciences Centre London Recruiting
Juravinski Cancer Centre Hamilton Recruiting
The Ottawa Hospital Cancer Centre Ottawa Recruiting
Northeastern Ontario Regional Cancer Centre Sudbury Recruiting
McGill University Health Centre Montreal Recruiting
Atlantic Clinical Cancer Research
QEIIHealth Sciences Centre
Halifax Recruiting

Trial ID: NCT01761929

Five Fraction Stereotactic Body Radiation Therapy (SBRT) Regimen, for Extra-Cranial Oligometastases in Solid Tumours (including Kidney Tumours)

Princess Margaret Cancer Centre/UHN Toronto Recruiting

Trial ID: NCT02499458
Prospective Validation of Circulating Tumour Cells and Circulating Endothelial Cells as Biomarkers in Clear Cell Renal Cancer
London Health Sciences Centre London Recruiting

Trial ID: NCT01062178
Efficacy of Ultrasound Contrast Agent to Assess Small Renal Masses and Distinguishing Renal Cell Carcinoma from Other Renal Masses, with Biopsy
Toronto General Hospital Toronto Recruiting

Help us keep the list current

Please note: This list is not intended to be exhaustive. Some clinical trials may not be listed here. To find more information and locations where the clinical trials are available within Canada go to:

For clinical trials in the United States and other global locations (including Canada), please see:

If you are aware of a trial for renal cell carcinoma that is not listed here, please let us know by e-mail so that we can share the information with others.

I found a clinical trial : What next?

If you find a clinical trial that may be of interest to you, take the information to your physician to discuss it in more detail. Please REGISTER with Kidney Cancer Canada and join the Discussion Forum to reach out to other patients participating in a clinical trial or to ask a specific question.

SHOULD I JOIN A CLINICAL TRIAL?